T3S-1124 - UMR-S 1124
Université Paris Descartes
45 rue des Saints Pères
75270 Paris Cedex 06
Fax : +33 (0) 1 42 86 38 68
Associate professor, MCU Paris Descartes
Addictions pharmacology and therapy
virginie.berthat@-Code to remove to avoid SPAM-parisdescartes.fr
Virginie Beray-Berthat holds a Pharm D (2000) and a PhD in Pharmacology from Paris Descartes University (2003). During her thesis, she worked on oxidative stress and inflammation in pre-clinical models of cerebral ischemia, under the supervision of Dr Isabelle Margaill and Pr Michel Plotkine in unit EA4475 (« Pharmacologie de la Circulation Cérébrale », Faculty of Pharmacy, Paris Descartes University).
Her post-doctoral intership at INSERM U289 (Pitié-Salpêtrière Hospital, Paris) in collaboration with Drs Etienne Hirsch and Stéphane Hunot focused on the neuroinflammation and the blood brain barrier permeability in experimental Parkinson’s disease.
In 2004, she was recruited as an associate professor in Pharmacology at the Faculty of Pharmacy of Paris Descartes University. In the research team « Pharmacologie de la Circulation Cérébrale » (unit EA4475 directed by Pr Michel Plotkine and then by Pr Catherine Marchand-Leroux), she worked on experimental cerebral ischemia in collaboration with Pr Isabelle Margaill, studying post-ischemic vascular damages related to neuroinflammation, hemorrhages, endothelial cells, blood brain barrier and microvesicles.
In 2019, she joined the team of Dr Florence Noble (PharmAddict CNRS ERL 3649) at Inserm UMR-S1124 (T3S “Environmental Toxicity, Therapeutic Targets, cellular Signaling and Biomarkers”) of Pr Robert Barouki, at the Saints Pères University Center (Paris University). She works now on the interactions between post-traumatic stress disorders and addiction, with a focus on neuroinflammation.
- Behavioral tests that reveal long-term deficits after permanent focal cerebral ischemia in mouse.
Fréchou M, Margaill I, Marchand-Leroux C, Beray-Berthat V : Behav Brain Res, 2019
- Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
El Amki M, Lerouet D, Garraud M, Teng F, Beray-Berthat V, Coqueran B, Barsacq B, Abbou C, Palmier B, Marchand-Leroux C, Margaill I : Mol Neurobiol, 2018
- Recombinant tissue plasminogen activator enhances microparticle release from mouse brain-derived endothelial cells through plasmin.
Garraud M, Khacef K, Vion AC, Leconte C, Yin M, Renard JM, Marchand-Leroux C, Boulanger CM, Margaill I, Beray-Berthat V : J Neurol Sci, 2016
- Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Haddad M, Beray-Berthat V, Coqueran B, Plotkine M, Marchand-Leroux C, Margaill I : Fundam Clin Pharmacol, 2013
- Detection of vascular cell adhesion molecule-1 expression with USPIO-enhanced molecular MRI in a mouse model of cerebral ischemia.
Fréchou M, Beray-Berthat V, Raynaud JS, Mériaux S, Gombert F, Lancelot E, Plotkine M, Marchand-Leroux C, Ballet S, Robert P, Louin G, Margaill I : Contrast Media Mol Imaging, 2013
- Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
Teng F, Beray-Berthat V, Coqueran B, Lesbats C, Kuntz M, Palmier B, Garraud M, Bedfert C, Slane N, Bérézowski V, Szeremeta F, Hachani J, Scherman D, Plotkine M, Doan BT, Marchand-Leroux C, Margaill I : Exp Neurol, 2013